 | |
| Clinical data | |
|---|---|
| Trade names | Posicor |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a607007 |
| Routes of administration |
By mouth (tablets) |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 70% |
| Protein binding | >99% |
| Metabolism | Liver (CYP3A4) |
| Elimination half-life | 17–25 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H38FN3O3 |
| Molar mass | 495.639 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 128 °C (262 °F) (dihydrochloride salt) |
| |
| |
  (what is this?) (verify)
| |
Mibefradil (trade name Posicor) was a pharmaceutical drug used for the treatment of hypertension and chronic angina pectoris. It is a nonselective calcium channel blocker. It was voluntary pulled from the market ten months after FDA approval, citing potential serious health hazards shown in post release studies.
The mechanism of action of mibefradil is characterized by the selective blockade of transient, low-voltage-activated (T-type) calcium channels over long-lasting, high-voltage-activated (L-type) calcium channels, which is probably responsible for many of its unique properties.
On June 8, 1998, Roche announced the voluntary withdrawal of the drug from the market, one year after approval by the FDA, due to the potential for drug interactions, some of them deadly, which may occur when it is taken together with some other medications.
